| | ||||||||||
| 1 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| PALIPERIDONE (is an active metabolite)
| PALIPERIDONE | NERVOUS SYSTEM | ORAL | Tmax 3 HOUR VD 391 LITER PPB 74 PERCENT Cl 10.8 LITER / HOUR (EQN) HT 25 HOUR SOLUBILITY PRACTICALLY INSOLUBLE IN WATER | 5-HYDROXYTRYPTAMINE 2A RECEPTOR D(2) DOPAMINE RECEPTOR ALPHA1 ADRENERGIC RECEPTOR ALPHA2 ADRENERGIC RECEPTOR H1 HISTAMINERGIC RECEPTOR | DOPAMINE D2 RECEPTOR ANTAGONIST CHEMBL217 DOPAMINE D2 RECEPTOR P14416 D(2) DOPAMINE RECEPTOR HOMO SAPIENS MEMBRANE RECEPTOR 7TM1 SMALLMOL MONOAMINE RECEPTOR DOPAMINE RECEPTOR | EMA | |||
| 2 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| PALIPERIDONE PALMITATE (has an active metabolite)
| PALIPERIDONE PALMITATE | NERVOUS SYSTEM | INTRAMUSCULAR | SOLUBILITY VERY SLIGHTLY SOLUBLE IN ETHANOL | 5-HYDROXYTRYPTAMINE 2A RECEPTOR D(2) DOPAMINE RECEPTOR ALPHA1 ADRENERGIC RECEPTOR ALPHA2 ADRENERGIC RECEPTOR H1 HISTAMINERGIC RECEPTOR | DOPAMINE D2 RECEPTOR ANTAGONIST CHEMBL217 DOPAMINE D2 RECEPTOR P14416 D(2) DOPAMINE RECEPTOR HOMO SAPIENS MEMBRANE RECEPTOR 7TM1 SMALLMOL MONOAMINE RECEPTOR DOPAMINE RECEPTOR | EMA | |||
| 3 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| PALIPERIDONE PALMITATE (has an active metabolite)
| PALIPERIDONE PALMITATE | NERVOUS SYSTEM | INTRAMUSCULAR | SOLUBILITY VERY SLIGHTLY SOLUBLE IN ETHANOL | 5-HYDROXYTRYPTAMINE 2A RECEPTOR D(2) DOPAMINE RECEPTOR ALPHA1 ADRENERGIC RECEPTOR ALPHA2 ADRENERGIC RECEPTOR H1 HISTAMINERGIC RECEPTOR | DOPAMINE D2 RECEPTOR ANTAGONIST CHEMBL217 DOPAMINE D2 RECEPTOR P14416 D(2) DOPAMINE RECEPTOR HOMO SAPIENS MEMBRANE RECEPTOR 7TM1 SMALLMOL MONOAMINE RECEPTOR DOPAMINE RECEPTOR | EMA | |||
| 4 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| RISPERIDONE (has an active metabolite)
| RISPERIDONE | NERVOUS SYSTEM | ORAL INTRAMUSCULAR SUBCUTANEOUS | Tmax 1 HOUR F 70 PERCENT VD 97.5 LITER (65 KILOGRAM) PPB 90 PERCENT Cl 21 LITER / HOUR HT 3 HOUR SOLUBILITY PRACTICALLY INSOLUBLE IN WATER | 5-HYDROXYTRYPTAMINE 2A RECEPTOR D(2) DOPAMINE RECEPTOR ALPHA 1 ADRENERGIC RECEPTOR ALPHA 2 ADRENERGIC RECEPTOR H1 HISTAMINIC RECEPTOR PDB 6C38 (STRUCTURE OF THE D2 DOPAMINE RECEPTOR BOUND TO THE ATYPICAL ANTIPSYCHOTIC DRUG RISPERIDONE) LIGAND CODE = 8NU (link to the list of PDB complexes) Download experimental 3D coordinates of 8NU with added hydrogens | DOPAMINE D2 RECEPTOR ANTAGONIST CHEMBL217 DOPAMINE D2 RECEPTOR P14416 D(2) DOPAMINE RECEPTOR HOMO SAPIENS MEMBRANE RECEPTOR 7TM1 SMALLMOL MONOAMINE RECEPTOR DOPAMINE RECEPTOR | EMA | |||
